GEAP201913960A - Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide - Google Patents
Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamideInfo
- Publication number
- GEAP201913960A GEAP201913960A GEAP201913960A GEAP2019013960A GEAP201913960A GE AP201913960 A GEAP201913960 A GE AP201913960A GE AP201913960 A GEAP201913960 A GE AP201913960A GE AP2019013960 A GEAP2019013960 A GE AP2019013960A GE AP201913960 A GEAP201913960 A GE AP201913960A
- Authority
- GE
- Georgia
- Prior art keywords
- metabolites
- dicarboxamide
- methyloxy
- quinolin
- cyclopropane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C305/00—Esters of sulfuric acids
- C07C305/22—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings
- C07C305/24—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
- Saccharide Compounds (AREA)
- Quinoline Compounds (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792413P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEAP201913960A true GEAP201913960A (en) | 2019-04-10 |
Family
ID=50631091
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201913960A GEAP201913960A (en) | 2013-03-15 | 2014-03-17 | Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| GEAP201413960A GEP20196995B (en) | 2013-03-15 | 2014-03-17 | Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201413960A GEP20196995B (en) | 2013-03-15 | 2014-03-17 | Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10273211B2 (https=) |
| EP (1) | EP2970126B1 (https=) |
| JP (1) | JP6389238B2 (https=) |
| KR (1) | KR102276348B1 (https=) |
| CN (1) | CN105121412B (https=) |
| AU (2) | AU2014232714B2 (https=) |
| BR (1) | BR112015023109A2 (https=) |
| CA (1) | CA2907334C (https=) |
| EA (1) | EA033786B1 (https=) |
| ES (1) | ES2729626T3 (https=) |
| GE (2) | GEAP201913960A (https=) |
| IL (1) | IL241577B (https=) |
| MX (1) | MX366003B (https=) |
| NZ (1) | NZ712330A (https=) |
| UA (1) | UA119321C2 (https=) |
| WO (1) | WO2014145715A1 (https=) |
| ZA (1) | ZA201506842B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX352926B (es) | 2010-09-27 | 2017-12-14 | Exelixis Inc | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos. |
| BR112013020362A2 (pt) | 2011-02-10 | 2018-05-29 | Exelixis Inc | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem |
| WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| CA2907334C (en) | 2013-03-15 | 2021-12-07 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| BR112016018450A2 (pt) | 2014-02-14 | 2018-09-18 | Exelixis Inc | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso |
| EP3119476A1 (en) * | 2014-03-17 | 2017-01-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
| EP3174854B1 (en) * | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| MX382904B (es) | 2014-08-05 | 2025-03-13 | Exelixis Inc | Combinaciones de fármacos para tratar mieloma múltiple. |
| EP3442531A1 (en) | 2016-04-15 | 2019-02-20 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| CN107556238A (zh) * | 2016-06-30 | 2018-01-09 | 深圳万乐药业有限公司 | 一种卡博替尼的合成方法 |
| CN117402114A (zh) | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| TWI831259B (zh) | 2018-06-15 | 2024-02-01 | 漢達生技醫藥股份有限公司 | 包含達沙替尼十二烷基硫酸鹽組合物的膠囊 |
| CN110423218A (zh) * | 2019-08-09 | 2019-11-08 | 新乡双鹭药业有限公司 | 一种苹果酸卡博替尼合成中杂质的制备方法 |
| CN120239695A (zh) * | 2022-12-01 | 2025-07-01 | 江苏奥赛康药业有限公司 | 一种制备卡博替尼及其中间体的方法 |
| WO2024163400A1 (en) | 2023-01-31 | 2024-08-08 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| US7977345B2 (en) | 2004-07-02 | 2011-07-12 | Exelixis, Inc. | c-MET modulators and method of use |
| EP1874759A4 (en) | 2005-04-06 | 2009-07-15 | Exelixis Inc | C-MET MODULATORS MODULATORS AND METHODS OF USE |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| PL2101759T3 (pl) | 2006-12-14 | 2019-05-31 | Exelixis Inc | Sposoby stosowania inhibitorów MEK |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| AR075084A1 (es) | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
| JP5486606B2 (ja) | 2008-11-13 | 2014-05-07 | エクセリクシス， インク． | キノリン誘導体の調製方法 |
| US20130030172A1 (en) | 2008-12-04 | 2013-01-31 | Exelixis, Inc. | Methods of Preparing Quinoline Derivatives |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| CN102510855B (zh) | 2009-07-17 | 2015-11-25 | 埃克塞里艾克西斯公司 | N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| AU2011224203A1 (en) | 2010-03-12 | 2012-10-04 | Exelixis, Inc | Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin -4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl] -N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| EA030435B1 (ru) | 2010-07-16 | 2018-08-31 | Экселиксис, Инк. | ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ |
| US20140186407A9 (en) | 2010-07-16 | 2014-07-03 | Exelixis Inc. | C-Met Modulator Pharmaceutical Compositions |
| US20140057908A1 (en) | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
| JP2013540759A (ja) | 2010-09-27 | 2013-11-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
| MX352926B (es) | 2010-09-27 | 2017-12-14 | Exelixis Inc | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos. |
| WO2012071321A1 (en) | 2010-11-22 | 2012-05-31 | Glaxosmithkline Llc | Method of treating cancer |
| SG191230A1 (en) | 2010-12-23 | 2013-07-31 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
| CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| BR112013020362A2 (pt) | 2011-02-10 | 2018-05-29 | Exelixis Inc | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| MX2013012695A (es) | 2011-05-02 | 2014-03-27 | Exelixis Inc | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. |
| TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| EP2758057B1 (en) | 2011-09-22 | 2017-05-31 | Exelixis, Inc. | Method for treating osteoporosis |
| CN104395284A (zh) | 2011-10-20 | 2015-03-04 | 埃克塞里艾克西斯公司 | 制备喹啉衍生物的方法 |
| IN2014CN04067A (https=) | 2011-11-08 | 2015-10-23 | Exelixis Inc | |
| WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| JP6513567B2 (ja) | 2012-09-07 | 2019-05-15 | エクセリクシス， インク． | 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤 |
| CN103664776B (zh) * | 2012-09-26 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种酪氨酸激酶抑制剂及其中间体的制备方法 |
| US20140221372A1 (en) | 2013-02-06 | 2014-08-07 | GlaxoSmithKline Intellectual Property (NO 2.) Limited | Method of administration and treatment |
| CA2907334C (en) | 2013-03-15 | 2021-12-07 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| WO2014145693A1 (en) * | 2013-03-15 | 2014-09-18 | Exelixis, Inc. | Metabolites of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| WO2014165779A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Drug combinations to treat cancer |
| US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| BR112016018450A2 (pt) | 2014-02-14 | 2018-09-18 | Exelixis Inc | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso |
| EP3119476A1 (en) * | 2014-03-17 | 2017-01-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
| EP3174854B1 (en) * | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
-
2014
- 2014-03-17 CA CA2907334A patent/CA2907334C/en active Active
- 2014-03-17 GE GEAP201913960A patent/GEAP201913960A/en unknown
- 2014-03-17 GE GEAP201413960A patent/GEP20196995B/en unknown
- 2014-03-17 NZ NZ712330A patent/NZ712330A/en unknown
- 2014-03-17 BR BR112015023109-8A patent/BR112015023109A2/en not_active Application Discontinuation
- 2014-03-17 UA UAA201510088A patent/UA119321C2/uk unknown
- 2014-03-17 KR KR1020157027712A patent/KR102276348B1/ko active Active
- 2014-03-17 EA EA201591756A patent/EA033786B1/ru not_active IP Right Cessation
- 2014-03-17 EP EP14721149.4A patent/EP2970126B1/en active Active
- 2014-03-17 MX MX2015012490A patent/MX366003B/es active IP Right Grant
- 2014-03-17 WO PCT/US2014/030524 patent/WO2014145715A1/en not_active Ceased
- 2014-03-17 AU AU2014232714A patent/AU2014232714B2/en active Active
- 2014-03-17 ES ES14721149T patent/ES2729626T3/es active Active
- 2014-03-17 CN CN201480021215.XA patent/CN105121412B/zh active Active
- 2014-03-17 JP JP2016503412A patent/JP6389238B2/ja active Active
- 2014-03-17 US US14/776,337 patent/US10273211B2/en active Active
-
2015
- 2015-09-10 IL IL24157715A patent/IL241577B/en active IP Right Grant
- 2015-09-15 ZA ZA2015/06842A patent/ZA201506842B/en unknown
-
2018
- 2018-06-27 AU AU2018204666A patent/AU2018204666A1/en not_active Abandoned
-
2019
- 2019-03-25 US US16/362,863 patent/US20190218182A1/en not_active Abandoned
-
2020
- 2020-09-24 US US17/031,196 patent/US20210002228A1/en not_active Abandoned
-
2024
- 2024-04-22 US US18/641,587 patent/US20240287002A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2907334A1 (en) | 2014-09-18 |
| WO2014145715A1 (en) | 2014-09-18 |
| EA201591756A1 (ru) | 2016-02-29 |
| NZ712330A (en) | 2020-04-24 |
| ES2729626T3 (es) | 2019-11-05 |
| MX2015012490A (es) | 2016-05-24 |
| US20160031818A1 (en) | 2016-02-04 |
| AU2014232714B2 (en) | 2018-07-19 |
| AU2014232714A1 (en) | 2015-10-08 |
| BR112015023109A2 (en) | 2018-05-15 |
| US20210002228A1 (en) | 2021-01-07 |
| ZA201506842B (en) | 2017-08-30 |
| AU2018204666A1 (en) | 2018-07-19 |
| MX366003B (es) | 2019-06-24 |
| CN105121412B (zh) | 2019-07-12 |
| US10273211B2 (en) | 2019-04-30 |
| GEP20196995B (en) | 2019-07-25 |
| US20240287002A1 (en) | 2024-08-29 |
| KR102276348B1 (ko) | 2021-07-12 |
| JP2016516074A (ja) | 2016-06-02 |
| EP2970126A1 (en) | 2016-01-20 |
| HK1220447A1 (en) | 2017-05-05 |
| UA119321C2 (uk) | 2019-06-10 |
| CA2907334C (en) | 2021-12-07 |
| CN105121412A (zh) | 2015-12-02 |
| IL241577B (en) | 2019-11-28 |
| EP2970126B1 (en) | 2019-03-06 |
| KR20150130376A (ko) | 2015-11-23 |
| JP6389238B2 (ja) | 2018-09-12 |
| EA033786B1 (ru) | 2019-11-26 |
| US20190218182A1 (en) | 2019-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20196995B (en) | Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide | |
| EA201691850A1 (ru) | Дозирование составов, содержащих кабозантиниб | |
| EA201490676A1 (ru) | Способ лечения остеопороза | |
| ZA201605424B (en) | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use | |
| AU2013225533A8 (en) | Amido spirocyclic amide and sulfonamide derivatives | |
| IL245117A0 (en) | Co-crystals of (n - (s-methyl-8-(1((2'-methyl-['4,5-bipyrimidine]-6-yl)amino)propane-2-yl)quinoline-4-carboxamide, Derivatives modified by their deuterium, methods for their preparation, preparations containing them and their uses | |
| IL244943B (en) | History of n-[3-(5-oxy-6-amino-pyrimidin-4-yl)phenyl]benzamide and pharmaceutical preparations that include them | |
| MX2015012622A (es) | Formulaciones eutecticas de clorhidrato de ciclobenzaprina y de clorhidrato de amitriptilina. | |
| MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
| MX2015013396A (es) | Derivados de quinolinas como nuevos agentes contra el cancer. | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| EP3279207A4 (en) | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | |
| UA116889C2 (uk) | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) | |
| GEP201706621B (en) | Benzamides | |
| WO2014153495A9 (en) | Novel stat3 inhibitors | |
| EA201590932A1 (ru) | Композиции, содержащие вортиоксетин и донепезил | |
| GEP201606595B (en) | (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel | |
| PH12017500348A1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| MX363530B (es) | Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo. | |
| IL230484A (en) | "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation | |
| EA201491517A1 (ru) | N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения | |
| EA201400444A1 (ru) | Производные 2-оксопиперидинила | |
| BR112014025416A2 (pt) | AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS. | |
| MX2015003034A (es) | Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso. |